Peptide Lab

Retatrutide 30 MG

$224.99

In stock

Retatrutide is an investigational peptide that activates three hormone receptors: GLP-1, GIP, and glucagon. This “triple-agonist” activity is being studied for its effects on body weight, blood-glucose regulation, and obesity-related conditions. Clinical trials have evaluated it as a once-weekly subcutaneous injection.

SKURC-ST-RETA-30MG
ManufacturerStrandix Peptides
FormLyophilized Powder
Strength30 mg
Size3 mL Vial
Reported ResultSee matching batch report
StockIn stock
Documentation StatusClient-supplied report available

Product Description

Retatrutide is an investigational peptide that activates three hormone receptors: GLP-1, GIP, and glucagon. This “triple-agonist” activity is being studied for its effects on body weight, blood-glucose regulation, and obesity-related conditions. Clinical trials have evaluated it as a once-weekly subcutaneous injection.

What research has shown:

Substantial weight loss in adults without diabetes: In the phase III TRIUMPH-1 trial involving 2,339 participants, average weight reduction at 80 weeks reached 25.0% in the highest-dose group, compared with 3.9% with placebo. These are group averages from a controlled trial, rather than guaranteed individual results.

Weight loss in adults with type 2 diabetes: The phase III TRIUMPH-2 trial reported average weight reductions of 18.8% in the highest-dose group, compared with 5.1% with placebo, at 80 weeks.

Improved blood-glucose control: TRIUMPH-2 also reported improvements in glycemic control, supporting continued investigation of retatrutide for people with obesity and type 2 diabetes.

Storage and handling: Keep unopened lyophilized material sealed, protected from light and moisture, and stored at the temperature specified by the manufacturer. Confirm sequence, counterion, assay, purity, water content, and stability on the COA. Do not publish reconstitution or administration instructions.

For laboratory research use only. Not for human or animal consumption.
Lab analysis

Third-party testing status.

Batch / LotReported ResultTestedPartnerStatusDocument
RT30/2026-04-06A99.949%; 99.938%May 7, 2026JanoshikClient-supplied reportView COA
22699.811%Mar 10, 2026Freedom DiagnosticsClient-supplied reportView COA